JP2016511273A - Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型 - Google Patents

Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型 Download PDF

Info

Publication number: JP2016511273A
Authority: JP; Japan
Prior art keywords: delafloxacin meglumine; drying; hours; delafloxacin; hydroxyazetidin
Prior art date: 2013-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2015561727A

Other languages

English (en)

Japanese (ja)

Inventor

ロジャーハンゼルマン、

マクスウェル、エム．リーヴ、

Original Assignee

メリンタセラピューティクス、インク

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-08

Filing date

2014-03-07

Publication date

2016-04-14

2014-03-07 Application filed by メリンタセラピューティクス、インク, メリンタセラピューティクス、インク filed Critical メリンタセラピューティクス、インク

2016-04-14 Publication of JP2016511273A publication Critical patent/JP2016511273A/ja

Status Pending legal-status Critical Current

Links

FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 title claims abstract description 40
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 title claims abstract description 40
235000010356 sorbitol Nutrition 0.000 title claims abstract description 40
229960002920 sorbitol Drugs 0.000 title claims abstract description 40
DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 title claims abstract description 13
239000013078 crystal Substances 0.000 title claims description 27
229950006412 delafloxacin Drugs 0.000 claims abstract description 93
238000000034 method Methods 0.000 claims abstract description 86
-1 6-amino-3,5-difluoropyridin-2-yl Chemical group 0.000 claims abstract description 80
239000000203 mixture Substances 0.000 claims abstract description 72
230000008569 process Effects 0.000 claims abstract description 9
AHJGUEMIZPMAMR-WZTVWXICSA-N 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F AHJGUEMIZPMAMR-WZTVWXICSA-N 0.000 claims description 48
238000001035 drying Methods 0.000 claims description 45
208000035143 Bacterial infection Diseases 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 9
208000022362 bacterial infectious disease Diseases 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
241000251468 Actinopterygii Species 0.000 claims description 7
230000037396 body weight Effects 0.000 claims description 3
JVLFMTZUPSBCNJ-UHFFFAOYSA-N 3,5-difluoropyridin-2-amine Chemical compound NC1=NC=C(F)C=C1F JVLFMTZUPSBCNJ-UHFFFAOYSA-N 0.000 claims 2
150000007942 carboxylates Chemical class 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 14
239000000126 substance Substances 0.000 abstract description 11
150000004684 trihydrates Chemical class 0.000 abstract description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 6
239000012453 solvate Substances 0.000 abstract description 3
239000003306 quinoline derived antiinfective agent Substances 0.000 abstract description 2
238000000634 powder X-ray diffraction Methods 0.000 description 25
239000003814 drug Substances 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 13
239000000523 sample Substances 0.000 description 13
239000000243 solution Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 10
230000005855 radiation Effects 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
238000004090 dissolution Methods 0.000 description 8
238000001565 modulated differential scanning calorimetry Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000010949 copper Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
238000001757 thermogravimetry curve Methods 0.000 description 7
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229910052802 copper Inorganic materials 0.000 description 6
239000000463 material Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
229960003194 meglumine Drugs 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
238000001802 infusion Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000002674 ointment Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000012296 anti-solvent Substances 0.000 description 3
235000019437 butane-1,3-diol Nutrition 0.000 description 3
239000004359 castor oil Substances 0.000 description 3
235000019438 castor oil Nutrition 0.000 description 3
235000005687 corn oil Nutrition 0.000 description 3
239000002285 corn oil Substances 0.000 description 3
235000012343 cottonseed oil Nutrition 0.000 description 3
239000002385 cottonseed oil Substances 0.000 description 3
238000000113 differential scanning calorimetry Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000008159 sesame oil Substances 0.000 description 3
235000011803 sesame oil Nutrition 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229940058015 1,3-butylene glycol Drugs 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
235000017060 Arachis glabrata Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
235000010777 Arachis hypogaea Nutrition 0.000 description 2
235000018262 Arachis monticola Nutrition 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
235000019485 Safflower oil Nutrition 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
239000000654 additive Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000010586 diagram Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
229940014259 gelatin Drugs 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000036541 health Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000036457 multidrug resistance Effects 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000006072 paste Substances 0.000 description 2
235000020232 peanut Nutrition 0.000 description 2
239000002304 perfume Substances 0.000 description 2
230000002974 pharmacogenomic effect Effects 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000003761 preservation solution Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000003813 safflower oil Substances 0.000 description 2
235000005713 safflower oil Nutrition 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
230000007704 transition Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
NNPYNRBQMKRPJY-UHFFFAOYSA-N 7-(3-hydroxyazetidin-1-yl)-4-oxo-1H-quinoline-3-carboxylic acid Chemical compound OC1CN(C1)C1=CC=C2C(C(=CNC2=C1)C(=O)O)=O NNPYNRBQMKRPJY-UHFFFAOYSA-N 0.000 description 1
NRCRUNRHMBFWAJ-UHFFFAOYSA-N 7-(3-hydroxyazetidin-1-yl)-4-oxo-3H-quinoline-3-carboxylic acid Chemical compound OC1CN(C1)C1=CC=C2C(C(C=NC2=C1)C(=O)O)=O NRCRUNRHMBFWAJ-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
206010056519 Abdominal infection Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010060968 Arthritis infective Diseases 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
239000004278 EU approved seasoning Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010014889 Enterococcal infections Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
241000282372 Panthera onca Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010058028 Shunt infection Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229940024545 aluminum hydroxide Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
238000010923 batch production Methods 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960001777 castor oil Drugs 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000013480 data collection Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
229960004667 ethyl cellulose Drugs 0.000 description 1
229940116333 ethyl lactate Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000011194 food seasoning agent Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
229960003907 linezolid Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000010687 lubricating oil Substances 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002762 monocarboxylic acid derivatives Chemical group 0.000 description 1
FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
229960003702 moxifloxacin Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000000162 organ preservation solution Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000010926 purge Methods 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002105 relative biological effectiveness Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
229910052594 sapphire Inorganic materials 0.000 description 1
239000010980 sapphire Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000012899 standard injection Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
210000001562 sternum Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

JP2015561727A 2013-03-08 2014-03-07 Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型 Pending JP2016511273A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361775089P	2013-03-08	2013-03-08
US61/775,089		2013-03-08
PCT/US2014/021946 WO2014138639A1 (en)	2013-03-08	2014-03-07	Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate

Publications (1)

Publication Number	Publication Date
JP2016511273A true JP2016511273A (ja)	2016-04-14

Family

ID=51492015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2015561727A Pending JP2016511273A (ja)	2013-03-08	2014-03-07	Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型

Country Status (14)

Country	Link
US (1)	US20160046603A1 (es)
EP (1)	EP2964652A4 (es)
JP (1)	JP2016511273A (es)
CN (1)	CN105189513A (es)
AR (1)	AR095203A1 (es)
AU (1)	AU2014225392A1 (es)
BR (1)	BR112015021725A2 (es)
CA (1)	CA2903755A1 (es)
EA (1)	EA201591668A1 (es)
HK (1)	HK1219476A1 (es)
IL (1)	IL241045A0 (es)
MX (1)	MX2015011651A (es)
TW (1)	TW201514165A (es)
WO (1)	WO2014138639A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105693695A (zh) *	2014-11-24	2016-06-22	重庆医药工业研究院有限责任公司	一种德拉沙星葡甲胺盐的晶型及其制备方法
CN105017223B (zh) *	2015-07-08	2017-08-01	扬子江药业集团有限公司	德拉沙星葡甲胺晶型i及其制备方法
CN105017224A (zh) *	2015-07-10	2015-11-04	扬子江药业集团有限公司	一种德拉沙星葡甲胺晶型的制备方法
CN106916142A (zh) *	2015-12-25	2017-07-04	江苏奥赛康药业股份有限公司	一种制备高纯度德拉沙星的方法
CN110467600A (zh) *	2018-05-10	2019-11-19	上海度德医药科技有限公司	一种德拉沙星葡甲胺盐晶型l及其制备方法
CN113018268B (zh) *	2019-12-25	2024-02-02	鲁南制药集团股份有限公司	一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
WO2022240897A1 (en) *	2021-05-10	2022-11-17	Sepelo Therapeutics, Llc	Pharmaceutical composition comprising delafloxacin for administration into the lung
CN116514775B (zh) *	2022-01-20	2024-11-29	安徽普利药业有限公司	一种徳拉沙星葡甲胺盐新晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57134482A (en) *	1981-02-13	1982-08-19	Dainippon Pharmaceut Co Ltd	1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
SI3056492T1 (sl) *	2004-10-08	2022-03-31	Abbvie Inc.	Sol meglumina in njene kristalinične oblike zdravila (delafloksacin)
US20070238719A1 (en) *	2005-05-10	2007-10-11	Hopkins Scott J	Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
TW200744598A (en) *	2005-09-28	2007-12-16	Daiichi Seiyaku Co	Process for the production of freeze-dried preparations containing quinolones
WO2008085913A1 (en) *	2007-01-04	2008-07-17	Rib-X Pharmaceuticals, Inc.	Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
MY161597A (en) *	2008-11-15	2017-04-28	Rib-X Pharmaceuticals Inc	Antimicrobial compositions

2014
- 2014-03-07 MX MX2015011651A patent/MX2015011651A/es unknown
- 2014-03-07 CA CA2903755A patent/CA2903755A1/en not_active Abandoned
- 2014-03-07 BR BR112015021725A patent/BR112015021725A2/pt not_active IP Right Cessation
- 2014-03-07 CN CN201480013112.9A patent/CN105189513A/zh active Pending
- 2014-03-07 WO PCT/US2014/021946 patent/WO2014138639A1/en not_active Ceased
- 2014-03-07 EP EP14760249.4A patent/EP2964652A4/en not_active Withdrawn
- 2014-03-07 HK HK16107424.3A patent/HK1219476A1/zh unknown
- 2014-03-07 AU AU2014225392A patent/AU2014225392A1/en not_active Abandoned
- 2014-03-07 EA EA201591668A patent/EA201591668A1/ru unknown
- 2014-03-07 US US14/773,655 patent/US20160046603A1/en not_active Abandoned
- 2014-03-07 JP JP2015561727A patent/JP2016511273A/ja active Pending
- 2014-03-10 AR ARP140100810A patent/AR095203A1/es unknown
- 2014-03-10 TW TW103108122A patent/TW201514165A/zh unknown
2015
- 2015-09-02 IL IL241045A patent/IL241045A0/en unknown

Also Published As

Publication number	Publication date
EP2964652A1 (en)	2016-01-13
AR095203A1 (es)	2015-09-30
BR112015021725A2 (pt)	2017-07-18
EP2964652A4 (en)	2016-10-12
CN105189513A (zh)	2015-12-23
EA201591668A1 (ru)	2016-02-29
WO2014138639A1 (en)	2014-09-12
AU2014225392A1 (en)	2015-09-24
HK1219476A1 (zh)	2017-04-07
TW201514165A (zh)	2015-04-16
CA2903755A1 (en)	2014-09-12
MX2015011651A (es)	2016-08-08
US20160046603A1 (en)	2016-02-18
IL241045A0 (en)	2015-11-30

Publication	Publication Date	Title
JP2016511273A (ja)	2016-04-14	Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型
JP6946194B2 (ja)	2021-10-06	キナーゼを調節する化合物の固体形態
TWI846166B (zh)	2024-06-21	{[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
JP6076267B2 (ja)	2017-02-08	リファキシミンの形態およびその使用
TW201444834A (zh)	2014-12-01	選擇性ｃｄｋ４／６抑制劑之固態形式
JP2015522010A (ja)	2015-08-03	リファキシミン及びアミノ酸を含む医薬組成物、その調製方法及びその使用
AU2019275075B2 (en)	2024-11-28	Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7H-imid azo [1,5- a] pyrazin-8-one
JP2020506196A (ja)	2020-02-27	テビペネムピボキシル結晶形、それを含む組成物、製造方法、および使用方
WO2015158202A1 (zh)	2015-10-22	一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途
JP5888612B2 (ja)	2016-03-22	縮合ピリジン化合物塩の結晶
US10828303B2 (en)	2020-11-10	Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
TW202245793A (zh)	2022-12-01	3-羥基-5-孕烷-20-酮衍生物的晶型及其製備方法和用途
JP2018510173A (ja)	2018-04-12	トピロキソスタットの新規結晶形及びその製造方法
TW202241846A (zh)	2022-11-01	具有ｅｐ拮抗活性之化合物的鹽、溶劑合物及結晶
CA3191776A1 (en)	2025-01-21	Salts of fenfluramine
NZ752311B2 (en)	2021-03-19	Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
CN111100122A (zh)	2020-05-05	左旋四氢帕马丁新化合物
JP2005527629A (ja)	2005-09-15	結晶性フルオロキノロン・アルギニン塩形態